In most western countries, the symptomatic management of Parkinson’s Disease (PD) is usually achieved with medicinal products including levodopa (LD), dopamine agonists, MAO‐B inhibitors, COMT inhibitors, antimuscarinics and amantadine. The control of the quality of the production of such medications is strict and the assessment of the benefit‐risk ratio of these ...